Breakthrough Therapy Designations
Executive Summary
Listing of all ‘breakthrough’ drugs, including status and basis of designation. Updated weekly.
You may also be interested in...
Cell/Gene Therapy Manufacturing Readiness Urged As A Condition For US Expedited Designation
Requiring that certain chemistry, manufacturing and controls conditions be satisfied before awarding breakthrough or regenerative medicine advanced therapy status would help ensure that the quality side of product development keeps pace with the clinical side, says Parexel's Mo Heidaran, a former CMC reviewer in the FDA’s biologics center.
Breakthrough Denial Doesn't Mean US FDA Won't Bring Full Resources To Application
Agency staff discuss how they offer early development advice to sponsors before a breakthrough decision is made and reassure them if the status is denied.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.